MX2009001208A - Compuestos cristalinos antifungicos. - Google Patents
Compuestos cristalinos antifungicos.Info
- Publication number
- MX2009001208A MX2009001208A MX2009001208A MX2009001208A MX2009001208A MX 2009001208 A MX2009001208 A MX 2009001208A MX 2009001208 A MX2009001208 A MX 2009001208A MX 2009001208 A MX2009001208 A MX 2009001208A MX 2009001208 A MX2009001208 A MX 2009001208A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- disorders
- compounds
- quinazolin
- difluorophenyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000000843 anti-fungal effect Effects 0.000 title 1
- 229940121375 antifungal agent Drugs 0.000 title 1
- UHIXWHUVLCAJQL-MPBGBICISA-N albaconazole Chemical compound C([C@@](O)([C@H](N1C(C2=CC=C(Cl)C=C2N=C1)=O)C)C=1C(=CC(F)=CC=1)F)N1C=NC=N1 UHIXWHUVLCAJQL-MPBGBICISA-N 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 206010017533 Fungal infection Diseases 0.000 abstract 2
- 208000031888 Mycoses Diseases 0.000 abstract 2
- 230000000813 microbial effect Effects 0.000 abstract 2
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 208000035269 cancer or benign tumor Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83586306P | 2006-08-07 | 2006-08-07 | |
| EP06380225A EP1887004A1 (en) | 2006-08-07 | 2006-08-07 | Crystalline forms of (1R,2R)-7-Chloro-3-[2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]quinazolin-4(3H)-one |
| US92940807P | 2007-06-26 | 2007-06-26 | |
| EP07380186A EP2009009A1 (en) | 2007-06-26 | 2007-06-26 | Crystalline antifungal compounds |
| PCT/US2007/017476 WO2008021049A2 (en) | 2006-08-07 | 2007-08-06 | Crystalline antifungal compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009001208A true MX2009001208A (es) | 2009-04-14 |
Family
ID=39082545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009001208A MX2009001208A (es) | 2006-08-07 | 2007-08-06 | Compuestos cristalinos antifungicos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7879867B2 (enExample) |
| EP (2) | EP2650291B1 (enExample) |
| JP (3) | JP2010513222A (enExample) |
| KR (1) | KR20090053903A (enExample) |
| CN (1) | CN103232442B (enExample) |
| AR (1) | AR062232A1 (enExample) |
| AU (1) | AU2007284851B2 (enExample) |
| BR (1) | BRPI0716026A2 (enExample) |
| CA (1) | CA2658843A1 (enExample) |
| DK (1) | DK2650291T3 (enExample) |
| ES (1) | ES2652670T3 (enExample) |
| IL (2) | IL196722A (enExample) |
| IN (1) | IN2014MN01560A (enExample) |
| MX (1) | MX2009001208A (enExample) |
| RU (1) | RU2500679C2 (enExample) |
| TW (1) | TWI426073B (enExample) |
| WO (1) | WO2008021049A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006018853A2 (en) | 2004-08-19 | 2006-02-23 | Hetero Drugs Limited | Novel polymorphs of efavirenz |
| ES2584838T3 (es) | 2006-04-05 | 2016-09-29 | Opko Health, Inc | Sal clorhidrato de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-espiro[4.5]decán-2-ona y procedimiento de preparación de la misma |
| ITMI20062449A1 (it) * | 2006-12-19 | 2008-06-20 | Dipharma Spa | Forma cristallina di rabeprazolo sodico |
| EP2434892B1 (en) * | 2009-05-29 | 2015-08-19 | Palau Pharma, S.A. | Azole antifungal compositions |
| KR20120079054A (ko) * | 2009-07-10 | 2012-07-11 | 에볼바 아게 | 디인 조성물 |
| CN105503870A (zh) * | 2009-08-14 | 2016-04-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| US9435692B2 (en) | 2014-02-05 | 2016-09-06 | Lam Research Corporation | Calculating power input to an array of thermal control elements to achieve a two-dimensional temperature output |
| US11039620B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US9622483B2 (en) | 2014-02-19 | 2017-04-18 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| US11039621B2 (en) | 2014-02-19 | 2021-06-22 | Corning Incorporated | Antimicrobial glass compositions, glasses and polymeric articles incorporating the same |
| GB201410407D0 (en) * | 2014-06-11 | 2014-07-23 | Univ Dundee And Syngene Internat Ltd Plc And Consejo Superior De Investigaciones Cientificas And Med | Treatment of chagas disease |
| EA025187B1 (ru) * | 2015-04-17 | 2016-11-30 | Тагир Аббасели оглы Сулейманов | Производное дитиокарбамата 2-((4-(4-метилпиперазин-1-ил)фенил)амино)-2-оксоетил4-этилпиперазин-1-карбодитиоат, обладающее антифунгальной активностью |
| JP2025505889A (ja) | 2021-12-22 | 2025-03-03 | パラウ ファルマ，エス．エル．ユー． | 多粒子アルバコナゾール組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0293500A1 (en) | 1987-06-01 | 1988-12-07 | American Cyanamid Company | 3-heteroalkyl-2,4.quinzaoline-diones |
| GB8819308D0 (en) | 1988-08-13 | 1988-09-14 | Pfizer Ltd | Triazole antifungal agents |
| TW218017B (enExample) | 1992-04-28 | 1993-12-21 | Takeda Pharm Industry Co Ltd | |
| TW297813B (enExample) * | 1993-09-24 | 1997-02-11 | Takeda Pharm Industry Co Ltd | |
| CA2134417A1 (en) | 1993-12-22 | 1995-06-23 | Katsumi Itoh | Optically active azole derivatives, their production and use |
| DK0783501T3 (da) * | 1995-08-02 | 2001-01-29 | Uriach & Cia Sa J | Pyrimidonderivater med anti-fungal aktivitet |
| AU6119798A (en) | 1997-03-05 | 1998-09-22 | Takeda Chemical Industries Ltd. | Crystalline form of a bis 1,2,4-triazole compound |
| ES2159488B1 (es) * | 2000-03-07 | 2002-04-16 | Uriach & Cia Sa J | Procedimiento para la preparacion de derivados de pirimidona con actividad antifungica. |
-
2007
- 2007-08-06 US US11/882,892 patent/US7879867B2/en active Active
- 2007-08-06 CN CN201210396409.0A patent/CN103232442B/zh not_active Expired - Fee Related
- 2007-08-06 RU RU2009104959/04A patent/RU2500679C2/ru active
- 2007-08-06 MX MX2009001208A patent/MX2009001208A/es active IP Right Grant
- 2007-08-06 ES ES13167750.2T patent/ES2652670T3/es active Active
- 2007-08-06 JP JP2009523811A patent/JP2010513222A/ja active Pending
- 2007-08-06 BR BRPI0716026-7A patent/BRPI0716026A2/pt not_active Application Discontinuation
- 2007-08-06 WO PCT/US2007/017476 patent/WO2008021049A2/en not_active Ceased
- 2007-08-06 KR KR1020097004839A patent/KR20090053903A/ko not_active Ceased
- 2007-08-06 TW TW096128916A patent/TWI426073B/zh not_active IP Right Cessation
- 2007-08-06 EP EP13167750.2A patent/EP2650291B1/en active Active
- 2007-08-06 EP EP20070836538 patent/EP2049504A4/en not_active Withdrawn
- 2007-08-06 DK DK13167750.2T patent/DK2650291T3/en active
- 2007-08-06 IN IN1560MUN2014 patent/IN2014MN01560A/en unknown
- 2007-08-06 AU AU2007284851A patent/AU2007284851B2/en not_active Ceased
- 2007-08-06 CA CA002658843A patent/CA2658843A1/en not_active Abandoned
- 2007-08-07 AR ARP070103473A patent/AR062232A1/es not_active Application Discontinuation
-
2009
- 2009-01-26 IL IL196722A patent/IL196722A/en active IP Right Grant
-
2010
- 2010-12-16 US US12/970,297 patent/US8258296B2/en not_active Expired - Fee Related
-
2013
- 2013-07-25 JP JP2013154163A patent/JP2014012673A/ja active Pending
-
2015
- 2015-07-09 JP JP2015137404A patent/JP2015193642A/ja active Pending
-
2016
- 2016-10-06 IL IL248216A patent/IL248216B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| US8258296B2 (en) | 2012-09-04 |
| IN2014MN01560A (enExample) | 2015-05-08 |
| AU2007284851A1 (en) | 2008-02-21 |
| CN103232442A (zh) | 2013-08-07 |
| RU2500679C2 (ru) | 2013-12-10 |
| EP2049504A2 (en) | 2009-04-22 |
| AU2007284851B2 (en) | 2013-05-09 |
| TWI426073B (zh) | 2014-02-11 |
| ES2652670T3 (es) | 2018-02-05 |
| BRPI0716026A2 (pt) | 2013-08-06 |
| EP2049504A4 (en) | 2010-09-22 |
| CA2658843A1 (en) | 2008-02-21 |
| WO2008021049A2 (en) | 2008-02-21 |
| TW200823197A (en) | 2008-06-01 |
| WO2008021049A3 (en) | 2008-12-31 |
| US20110092702A1 (en) | 2011-04-21 |
| WO2008021049A9 (en) | 2008-10-30 |
| IL196722A (en) | 2016-10-31 |
| KR20090053903A (ko) | 2009-05-28 |
| US20080076787A1 (en) | 2008-03-27 |
| AR062232A1 (es) | 2008-10-22 |
| JP2014012673A (ja) | 2014-01-23 |
| EP2650291B1 (en) | 2017-10-04 |
| DK2650291T3 (en) | 2017-10-23 |
| IL196722A0 (en) | 2009-11-18 |
| JP2010513222A (ja) | 2010-04-30 |
| EP2650291A1 (en) | 2013-10-16 |
| RU2009104959A (ru) | 2010-08-20 |
| JP2015193642A (ja) | 2015-11-05 |
| IL248216B (en) | 2018-03-29 |
| US7879867B2 (en) | 2011-02-01 |
| CN103232442B (zh) | 2015-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009001208A (es) | Compuestos cristalinos antifungicos. | |
| MY157177A (en) | Heteroaryl compounds useful as inhibitors of e1 activating enzymes | |
| SG169369A1 (en) | Inhibitors of e1 activating enzymes | |
| MY149957A (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| ATE534632T1 (de) | Thiazole, imidazole und pyrazole als proteinkinasehemmer | |
| WO2010038086A3 (en) | P38 map kinase inhibitors | |
| EP2484679A3 (en) | N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors | |
| CL2011000480A1 (es) | Compuestos derivados de amino-1,2,4-triazolo[1,5-a]piridina sustituidos, inhibidores de quinasa; composicion farmaceutica; y su uso para el tratamiento o prevencion de condiciones inflamatorias, inmunologicas, autoinmunes, alergicas, reumaticas, tromboticas, cancer, infecciones, padecimientos neurodegenerativos, entre otras. | |
| GEP20125564B (en) | Pyrimidine derivatives as kinase inhibitors | |
| WO2010056378A3 (en) | Extracellular matrix compositions for the treatment of cancer | |
| MX2009009948A (es) | Derivados de piridazinona utiles como inhibidores de glucano sintasa. | |
| WO2008083367A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
| WO2010005876A3 (en) | Polycyclic heteroaryl substituted triazoles useful as axl inhibitors | |
| WO2006106326A8 (en) | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors | |
| CL2011001863A1 (es) | Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07). | |
| WO2007084391A3 (en) | Thiazole compounds as protein kinase b ( pkb) inhibitors | |
| WO2009012109A3 (en) | Cyanine-containing compounds for cancer imaging and treatment | |
| WO2010000364A8 (de) | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate | |
| CL2011000489A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala | |
| WO2010002779A3 (en) | Naphthyridininones as aurora kinase inhibitors | |
| WO2007097981A3 (en) | Alpha carbolines and uses thereof | |
| WO2009158371A8 (en) | Inhibitors of akt activity | |
| WO2017155942A3 (en) | Substituted heterocycles as c-myc targeting agents | |
| NZ599289A (en) | Antimicrobial compounds and methods of making and using the same | |
| UA84954C2 (ru) | Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: PALAU PHARMA, S.A. |
|
| FG | Grant or registration |